Document Classification

Section Type: RESULTS

Text: The proportion of patients with a response of 0 or 1 on the modified investigator 's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept : in the ERASURE study, the rates were 65. 3 % with 300 mg of secukinumab, 51. 2 % with 150 mg of secukinumab, and 2. 4 % with placebo ; in the FIXTURE study, the rates were 62. 5 % with 300 mg of secukinumab, 51. 1 % with 150 mg of secukinumab, 27. 2 % with etanercept, and 2. 8 % with placebo (P < 0. 001 for each secukinumab dose vs. comparators).